Immunotherapy before surgery for head and neck cancer
Part of Cancer clinical trials.
This study tests a drug called pabliximab (an immunotherapy) given before surgery to shrink head and neck tumors. It aims to make surgery more effective and may improve outcomes for people with this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of throat or voice-box cancer (called squamous cell carcinoma) that is at stage III or IVA, and your doctor believes it can be removed with surgery.
- You feel well enough to do daily activities (a score of 0 or 1 on the ECOG scale)
- Your tumor has been tested and shows a certain protein called PD-L1.
- Your blood counts, kidney, and liver function are within acceptable limits.
- You are not pregnant (if female) and are willing to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a new immunotherapy drug (pucotenlimab) combined with chemotherapy before surgery for head and neck cancer. The goal is to see if this combination shrinks the tumor and improves outcomes for patients with locally advanced disease.
This trial tests a combination of drugs before surgery for head and neck cancer. It aims to shrink tumors and improve outcomes, and the study compares adding another targeted drug to the standard combination.
This trial tests giving a combination of chemotherapy and immunotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of targeted immunotherapy and chemotherapy given before surgery or radiation for head and neck cancer. The goal is to shrink the tumor and potentially improve outcomes.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.